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OBJECTIVES We sought to evaluate in vivo and in vitro left ventricular (LV) geometry and function in
streptozotocin-induced diabetic rats and the possible role of the nitric oxide (NO) pathway.
BACKGROUND Diabetes results in cardiac dysfunction; however, the specific abnormalities are unknown.
Because decreased NO contributes to abnormal vascular function in diabetics, we hypothe-
sized that NO pathway abnormalities may contribute to diabetic cardiomyopathy.
METHODS Control rats and those with non–insulin-dependent diabetes mellitus (NIDDM) underwent
echocardiography, hemodynamic assessment, isolated heart perfusion and measurement of
exhaled NO and LV endothelial constitutive nitric oxide synthase (ecNOS).
RESULTS Diabetic rats had increased LV mass (3.3 6 0.6 vs. 2.6 6 0.3 g/g body weight [BW], p ,
0.001) and cavity dimensions (diastolic 2.0 6 0.1 vs. 1.8 6 0.2 cm/cm tibial length [TL], p ,
0.05). Diabetic rats had prolonged isovolumic relaxation time (IVRT) (40 6 8 vs. 26 6 6 ms,
p , 0.0001), increased atrial contribution to diastolic filling (0.47 6 0.09 vs. 0.30 6 0.08 m/s,
p , 0.0001), and elevated in vivo LV end-diastolic pressure (7 6 6 vs. 2 6 1 mm Hg, p 5
0.04). Diabetic rats had increased chamber stiffness. Shortening was similar in both groups,
despite reduced meridional wall stress in diabetics, suggesting impaired systolic contractility.
Exhaled NO was lower in diabetic rats (1.8 6 0.2 vs. 3.3 6 0.3 parts per billion, p , 0.01)
and correlated with Doppler LV filling. The ecNOS was similar between the groups.
CONCLUSIONS Diabetic cardiomyopathy is characterized by LV systolic and diastolic dysfunction, the latter
correlating with decreased exhaled NO. The NO pathway is intact, suggesting impaired
availability of NO as contributor to cardiomyopathy. (J Am Coll Cardiol 1999;34:2111–9) ©
1999 by the American College of Cardiology
Cardiovascular disease is the leading cause of death in
diabetic patients (1). Both insulin-dependent diabetes mel-
litus (IDDM) and non–insulin-dependent diabetes mellitus
(NIDDM) may result in myocardial dysfunction in the
absence of coronary artery disease, valvular pathology or
systemic hypertension (2,3). This diabetic cardiomyopathy
has been postulated to contribute to both the higher
incidence of congestive heart failure observed in longitudi-
nal studies in diabetic patients without coronary artery
disease and the higher in-hospital and long-term mortality
after myocardial infarction in diabetic patients (3,4). How-
ever, the exact nature and mechanism(s) of cardiomyopathy
are unknown.
Peripheral vascular endothelium-dependent vasodilation
is impaired in patients with diabetes mellitus and experi-
mentally induced hyperglycemia, probably as a result of the
decreased availability of endothelial nitric oxide (NO) (5,6).
Because NO also directly affects cardiac function (7), we
hypothesized that reduced NO availability may also con-
tribute to diabetic cardiomyopathy. Clinical studies in pa-
tients with diabetes have been limited by the influences of
other coexisting cardiovascular diseases, such as hyperten-
sion and coronary artery disease. Therefore, experimentally
induced animal models of diabetes have been developed to
study cardiomyopathy (8). However, the evaluation of
cardiac dysfunction has proven difficult in these small
animal models of diabetes, primarily owing to the difficulty
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in obtaining invasive in vivo and in vitro hemodynamic
studies. Previous studies have validated two-dimensional
Doppler echocardiography in characterizing left ventricular
(LV) geometry and function in a rat model of myocardial
infarction (9,10). The aim of this study was therefore
twofold: 1) to comprehensively evaluate in vivo LV geometry
and function (systolic and diastolic) in the streptozotocin
(STZ)-induced NIDDM rat utilizing Doppler echocardi-
ography and to integrate this noninvasive assessment of
cardiac function with data obtained from invasive in vivo
hemodynamic assessment and in vitro isolated heart perfu-
sion; and 2) to evaluate the contribution of the NO pathway
to the abnormal cardiac function in the NIDDM rat.
METHODS
Study population and creation of diabetes. The experi-
mental procedures were approved by the Beth Israel Dea-
coness Medical Center’s Institutional Animal Care and Use
Committee (IACUC) and Taconic Farm’s (Germantown,
New York) IACUC. The National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals was
followed. Sixty-two Sprague-Dawley female rats weighing
140 to 189 g were assigned to two groups. Rats were
anesthetized with ketamine hydrochloride (85 mg/kg body
weight) intramuscularly (IM). Control rats (n 5 14) re-
ceived intravenous (IV) saline through the tail vein (place-
bo). The diabetic group (n 5 48) received an IV injection
through the tail vein of freshly prepared pancreatic-cell
toxin STZ 50 mg/kg. This dose produces a nonketotic
model of diabetes mellitus (11,12).
Four days after placebo or STZ, nonfasted animals were
anesthetized with ketamine hydrochloride (85 mg/kg) and
thorazine (3.75 mg/kg) IM to allow for a reduced-stress
blood collection. A 5-mm section of the tail tip was cut and
blood was expressed onto One Touch (Johnson & Johnson)
glucose test strips and read in a One Touch II blood glucose
meter. Readings were taken in duplicate for each animal and
averaged. When individual readings varied by .15%, a third
reading was taken and included in the average.
Streptozotocin-treated animals with a mean nonfasted
blood glucose level .200 mg/dl were determined to be
diabetic; all others were excluded from the study. Sampling
was performed between 11:30 AM and 3:30 PM on the same
day to standardize for blood glucose fluctuations. Nineteen
rats were excluded from the STZ group and the study for
failure to develop diabetes, leaving 29 rats in the STZ
group.
Echocardiography. Two and a half months after placebo
or STZ, transthoracic echocardiograms were performed in
control (n 5 14) and diabetic (n 5 29) animals as previously
described (9). Rats were anesthetized with a combination of
ketamine hydrochloride 50 mg/kg intraperitoneally (IP)
(Parke Davis, Morris Plains, New Jersey) and xylazine
10 mg/kg IP (Lloyd Laboratories, Shenandoa, Iowa). Echo-
cardiograms were performed with a Hewlett-Packard Sonos
2500 (Andover, Massachusetts) sector scanner equipped
with a 7.5-MHz phased-array transducer. Animals were
scanned from below, at 2-cm depth with focus optimized at
1 cm. Because the leading edge of the anterior wall was not
identifiable consistently, in part secondary to chest wall
artifact, the anterior edge of the anterior wall was measured
by the trailing-edge method (13). The posterior edge and
posterior wall thickness and LV internal dimensions were
measured according to the leading-edge method of the
American Society of Echocardiography (14). We have
demonstrated previously the reproducibility and excellent
correlation with ex vivo mass of the aforementioned digi-
tizing protocol (9). All measurements were based on the
average of three consecutive cardiac cycles. Two-
dimensionally guided pulsed Doppler recordings of LV
in-flow were obtained from the apical four-chamber view.
Maximal early (E) and late (A) diastolic flow velocities were
derived from mitral in-flow velocities. The LV outflow tract
diameter was measured on a still-frame two-dimensional
image at the base of the aortic leaflets in a parasternal
long-axis view. The LV outflow tract velocity was measured
just below the aortic valve, from an apical five-chamber
view. Cardiac output (ml/kg per min) was calculated as
previously described (9). The sample volume was then
placed between the mitral valve and LV outflow tract so that
the aortic valve closure line and the onset of mitral flow
could be clearly identified. Isovolumic relaxation time
(IVRT) was taken as the time from aortic valve closure to
the onset of mitral flow.
Allometric relations exist between cardiac and body size
measurements. However, the correct method to use in the
rat is unknown. The LV mass was normalized to body
weight (BW) (9,15). The linear measurements of LV wall
thicknesses and chamber dimensions were normalized to the
linear measurement of tibial length (TL), an index of
growth that is independent of body fat or fluid homeostasis
(16). Tibial length was measured by radiography after rat
death, as previously described (10).
Measurement of exhaled NO. Between 12 and 24 h after
echocardiography, five control and eight diabetic rats were
anesthetized with ketamine and xylazine at the same doses
used for echocardiography. The animals were intubated
with an endotracheal tube through a small midline trache-
Abbreviations and Acronyms
BW 5 body weight
ecNOS 5 endothelial constitutive nitric oxide synthase
IDDM 5 insulin-dependent diabetes mellitus
IVRT 5 isovolumic relaxation time
LV 5 left ventricle
NIDDM 5 non–insulin-dependent diabetes mellitus
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TL 5 tibial length
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ostomy and mechanically ventilated with a rodent volume
ventilator (Harvard Apparatus, South Natick, Massachu-
setts) at a tidal volume of 20 ml/kg, ratio of inspiratory to
expiratory time 1.0 and respiratory rate 52 breaths/min. The
inspired oxygen fraction was 0.21 from a medical air
cylinder containing only oxygen and nitrogen (Airco/New
England, Hingham, Massachusetts). After a 2-min stabili-
zation period, gas was collected from the expiratory port of
the ventilator for three 2-min periods, and the results were
averaged. The NO content was immediately analyzed by
chemiluminescence (NO analyzer model 42S [low level],
Thermo Environmental Instruments Inc., Franklin, Massa-
chusetts). Briefly, the measurement of NO by chemilumi-
nescence involves light generation from a chemical reaction
between NO in the sample and ozone in the reaction
chamber (17). A photomultiplier tube produces an electrical
signal proportional to the light generated from the reaction
between NO in the sample and ozone. The NO analyzer
was calibrated using a reference gas of known NO concen-
tration. Expired NO is expressed as the concentration of
NO in expired gas in parts per billion (ppb). The minimal
detectable limit is 50 ppb (data on file from Thermo
Environmental Instruments Inc.).
In vivo hemodynamic studies. In a subgroup of 17 animals
(6 control, 11 diabetic) a calibrated 2F micromanometer-
tipped catheter (Millar Instruments, Houston, Texas) was
passed through the right carotid artery into the LV under
constant pressure monitoring. Before instrumentation, rats
were anesthetized with ketamine and xylazine at the same
doses used for echocardiography. The LV end-diastolic
pressure was recorded with an expanded scale. An estima-
tion of vascular resistance was calculated as mean arterial
blood pressure/cardiac output normalized to BW. Midwall
fractional shortening was calculated as described by de
Simone et al. (18). The meridional wall stress was calculated
as described by Litwin et al. (13).
Blood analysis. Immediately after cardiac catheterization,
1 ml of blood was collected through direct cardiac puncture
for measurement of serum fructosamine levels by a reduc-
tion method with nitroblue tetrazolium (19). Serum fruc-
tosamine levels give an indication of fluctuations in blood
glucose levels that occur over a two- to three-month period
(19).
In vitro isolated heart perfusion. A separate subgroup of
six control and nine diabetic animals underwent isolated
heart perfusion. Isolated hearts were placed in an isovolu-
mic, buffer-perfused rat heart preparation according to the
Langendorff technique, as previously described (10). Retro-
grade aortic perfusion of the coronary arteries was per-
formed through a constant flow of 10 ml/min per g heart
weight (20). The composition of the perfusate was as
follows (mmol/liter): NaCl 118, KCl 4.7, KH2PO4 1.2,
CaCl2 1.0, MgCl2 1.2, NaHCO3 23 and dextrose 10.0, and
was saturated with a 95% O2 and 5% CO2 gas mixture to a
pH of 7.4 6 0.2. The LV pressure was measured using a
fluid-filled latex balloon, and hearts were paced at 2.5 Hz.
Measurements of LV function were obtained when the
preparation achieved a steady state (;15 min); the balloon
volume was then set to the lowest volume at which minimal
LV pressure tracings (,1 mm Hg) could be recorded. This
volume was defined as the zero volume (V0). The LV
volume was then further increased in steps of 10 to 20 ml.
The LV functional variables were obtained 1 to 2 min after
each increment of volume when a new steady state was
reached. The LV volume was increased up to a value
(volmax) at which maximal peak-developed pressure was
reached and a further increase in balloon volume led to a
decrease of developed pressure. To achieve comparable
loading conditions (i.e., balloon volumes) in hearts of
different sizes, the LV variable of interest was plotted versus
vol/volmax. This method of normalization has recently been
validated in our laboratory by showing that control hearts of
different sizes reveal superimposable pressure-volume
curves, as well as superimposable relaxation and contractility
curves once the intracardiac balloon volume is normalized
by volmax (21). Differences in LV functional variables at
balloon volume normalized by volmax can therefore be
ascribed to intrinsic changes of cardiac properties. Because
studying the whole heart function at 100% of volmax would
represent a situation of unphysiologic preload, we compared
function at 50% volmax (22).
Biochemistry. Immediately after catheterization and blood
collection, five control and five diabetic hearts were excised
and arrested in ice-cold Krebs-Henselite solution. The LV
tissue was rapidly placed into liquid nitrogen and stored at
270°C. To obtain total muscle cell protein, the frozen LVs
were ground to a fine powder and resuspended in a modified
RIPA buffer (9.1 mmol/liter dibasic sodium phosphate,
1.7 mmol/liter monobasic sodium phosphate, 150 mmol/
liter sodium chloride, pH 7.4, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate, phenyl-
methylsulfonylfluoride at 10 mg/ml, pepstatin A at 1 mg/ml,
leupeptin at 1 mg/ml and dithiothreitol at 1 mmol/liter).
Samples were centrifuged at 14,000 rpm. Determination of
the protein concentrations of the resultant supranatant were
made by the method of Bradford using bovine serum
albumin as a standard (23) or by the biuret reaction (24).
The LV control and diabetic total cell lysates (either 50 or
100 mg) were electrophoresed in 7.5% or 4% to 20%
gradient polyacrylamide/sodium dodecyl sulfate gels (25).
Gels were then either stained with Coomassie brilliant blue
R-250 or transferred onto nitrocellulose electrophoretically
using a minitransblot electrophoretic transfer cell (Biorad,
Hercules, California). Western blotting was performed by
standard procedures (as described in Biorad). A polyclonal
antibody for endothelial constitutive nitric oxide synthase
(ecNOS) was obtained from Affinity Bioreagents, Inc.
(Golden, Colorado). The secondary antibody (goat anti-
rabbit) conjugated to horse radish peroxidase allowed de-
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tection of immobilized ecNOS by a chemiluminescent
system (ECL, Amersham Life Sciences, Buckinghamshire,
United Kingdom). Human endothelial cell lysates (Trans-
duction Laboratories, Lexington, Kentucky) were used as a
positive control. Band densities on the exposed films were
then quantitated on a gel scanner using Molecular Dynam-
ics Image Quant Version 3.0 software.
Statistics. Data are expressed as the mean value 6 SEM in
the figures and tables. Parametric data were compared using
the Student t test or paired t-test as appropriate. Nonpara-
metric data were compared using the Wilcoxon two-sample
test. Pressure–volume data may be fitted to a monoexpo-
nential function to derive chamber stiffness. However, the
real relation is frequently curvilinear (26). Therefore, the
overall difference between the diabetic and control curves
was analyzed by repeated-measures analysis of variance. A p
value ,0.05 was considered significant. Data were analyzed
using Microsoft Excel, SPSS and SAS statistical packages.
RESULTS
Body Weight, Blood Glucose
and Serum Fructosamine Levels
Diabetic animals gained significantly less weight than con-
trol animals. Blood glucose and serum fructosamine levels
were significantly elevated in diabetic animals as compared
with control animals (Table 1).
Echocardiography
M-mode measurements. Diabetic animals had a signifi-
cantly greater LV mass per BW as compared with control
animals (Table 2). Systolic and diastolic wall thicknesses
were similar in both groups, whereas cavity dimensions were
significantly greater in diabetic animals as compared with
control animals, corrected for TL. Relative wall thickness
was not different between the two groups, indicating a
pattern of eccentric hypertrophy in diabetic animals (27).
Both endocardial fractional shortening and midwall frac-
tional shortening were not different between the two groups.
However, meridional wall stress was significantly lower in
the diabetic animals as compared with the control animals.
Because both midwall and fractional shortening were similar
in both groups despite a lower wall stress in the diabetic
animals, this finding suggests that the diabetic animals
exhibited impaired myocardial systolic function.
Doppler measurements. SYSTOLIC VARIABLES. Heart
rates were significantly lower in diabetic animals (Table 3).
Stroke volumes were higher in diabetic animals, resulting in
a higher cardiac output in the diabetic group. Peripheral
vascular resistance was similar between the two groups,
making it unlikely that a reduced peripheral vascular resis-
tance resulted in the higher cardiac output observed in the
diabetic group.
DIASTOLIC VARIABLES. Diabetic animals were character-
ized by impaired LV relaxation and filling (Table 4). This
included significantly longer IVRT and an increased depen-
dence on the atrial contribution to diastolic filling (greater
peak A and reduced E/A ratio) as compared with control
animals. Impaired LV relaxation and filling were not cor-
related with heart rate in the control or diabetic groups
Table 1. Body Weight, Blood Glucose and Serum Fructosamine
Control
Group
(n 5 14)
Diabetic
Group
(n 5 29)
Final BW (g) 285 6 6 188 6 5*
Weight gain (g) 108 6 6 32 6 5*
Blood glucose (mg/dl) 81 6 2 267 6 5*
Final fructosamine 139 6 7 245 6 22*
(mg/dl) (n 5 7) (n 5 11)
*p , 0.0001 versus control group. Data are presented as mean value 6 SEM.
BW 5 body weight.
Table 2. M-Mode Measurements
Control
Group
(n 5 14)
Diabetic
Group
(n 5 19)
LV mass/BW (mg/g) 2.6 6 0.3 3.3 6 0.6*
AWTd/TB (cm/cm) 0.4 6 0.1 0.4 6 0.1
AWTs/TB (cm/cm) 0.7 6 0.1 0.7 6 0.1
PWTd/TB (cm/cm) 0.4 6 0.1 0.4 6 0.7
PWTs/TB (cm/cm) 0.7 6 0.1 0.8 6 0.1
LVd/TB (cm/cm) 1.8 6 0.2 2.0 6 0.1†
LVs/TB (cm/cm) 0.5 6 0.0 0.6 6 0.0‡
RWT 0.4 6 0.1 0.3 6 0.1
Endocardial FS (%) 50 6 6 50 6 7
Midwall FS (%) 11 6 5 11 6 4
Meridional stress (kdyne/cm2) 37 6 4 25 6 8§
*p , 0.001; †p , 0.05; ‡p , 0.0001; §p , 0.01. Data are presented as the mean
value 6 SEM.
AWTd 5 anterior wall thickness in diastole; AWTs 5 anterior wall thickness in
systole; BW 5 body weight; FS 5 fractional shortening; LVd 5 left ventricular
internal dimension in diastole; LVs 5 left ventricular internal dimensions in systole;
PWTd 5 posterior wall thickness in diastole; PWTs 5 posterior wall thickness in
systole; RWT 5 relative wall thickness; TB 5 tibial length.
Table 3. Systolic Doppler Measurements
Control
Group
(n 5 14)
Diabetic
Group
(n 5 19)
Heart rate (beats/min) 250 6 16 212 6 25*
Acceleration time (ms) 20 6 10 24 6 10
Deceleration time (ms) 80 6 10 113 6 20*
Stroke volume/BW (ml/kg) 0.92 6 0.17 1.56 6 0.41*
Cardiac output/BW (ml/kg
per min)
231 6 45 327 6 81*
PVR/BW (arbitrary units) 0.6 6 0.1 0.6 6 0.2
(n 5 6) (n 5 11)
*p , 0.0001. Data are presented as the mean value 6 SEM.
BW 5 body weight; PVR 5 peripheral vascular resistance.
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(peak A, E/A, IVRT: all r , 0.40, p . 0.05), excluding an
influence of heart rate on the impaired diastolic variables.
Expired NO Levels
Mixed expired NO levels were lower in the diabetic group
than in the control group (1.78 6 0.16 vs. 3.26 6 0.30 ppb,
p , 0.01). Mixed expired NO levels were correlated with a
greater dependence of atrial filling (greater peak A velocity)
to total diastolic filling (r 5 20.7, p 5 0.08 [borderline
significance]), a reduced E/A ratio (r 5 0.7, p , 0.01) and
prolonged IVRT (r 5 20.5, p , 0.05) in all animals (Fig.
1). There was no significant correlation within each group
between expired NO and the echocardiographic variables of
cardiac function.
In Vivo and In Vitro Hemodynamic Studies
Peak LV systolic pressure, aortic diastolic pressure and
mean arterial pressure were significantly lower in diabetic
animals (Table 5). The mean LV end-diastolic pressure was
significantly higher in diabetic animals than in control
animals.
In vitro coronary perfusion pressure was not different
between the two groups (Table 5). Peak LV systolic
pressure, developed pressure and 1dP/dtmax were signifi-
cantly lower in the diabetic animals than in the control
animals. The LV end-diastolic pressure did not differ
between the diabetic and control animals. The 2dP/dtmin
was significantly less negative in the diabetic group than in
the control group. The diabetic diastolic pressure–volume
relation was shifted to the left, with a significant change in
the shape of the curve, indicating increased chamber stiff-
ness (Fig. 2).
Comparison of ecNOS Expression
Western blots of cell lysates from control and diabetic LVs
were performed to determine if any differences in the
relative expression of the ecNOS protein existed between
control (n 5 4) and diabetic hearts (n 5 4) (Fig. 3). There
was no difference in relative ecNOS protein levels (con-
trol 5 129,529 6 9,275, diabetic 5 129,222 6 14,662, p 5
NS; expressed as a percentage: control 100%, diabetic
99.7%).
DISCUSSION
The present study provides an integrated approach to the
assessment of cardiac function in the diabetic rat, utilizing
both Doppler echocardiographic and invasive hemodynamic
Table 4. Diastolic Doppler Measurements
Control Group
(n 5 14)
Diabetic Group
(n 5 19)
IVRT (ms) 26 6 6 40 6 8*
Peak E (m/s) 0.70 6 0.07 0.75 6 0.11
Peak A (m/s) 0.30 6 0.08 0.47 6 0.09*
Peak E/A 2.52 6 0.81 1.64 6 0.36†
VTIE (cm/s) 0.03 6 0.00 0.03 6 0.00‡
VTIA (cm/s) 0.01 6 0.00 0.02 6 0.01*
*p , 0.0001; †p , 0.01; ‡p , 0.001. Data are presented as the mean value 6 SEM.
IVRT 5 isovolumic relaxation time; Peak A 5 peak velocity of late filling; Peak
E 5 peak velocity of early filling; VTIA 5 velocity time integral of late filling;
VTIE 5 velocity time integral of early filling.
Figure 1. Exhaled NO versus diastolic filling pattern. Mixed
expired NO levels were strongly correlated with a greater atrial
contribution to diastolic filling (reduced E/A ratio) in all animals.
Circles 5 diabetic animals; squares 5 control animals.
Table 5. Mechanical Variables In Vivo and in the Isolated
Whole Heart
Control Group
(n 5 6)
In Vivo
Diabetic Group
(n 5 11)
In Vivo
Peak LV systolic
pressure (mm Hg)
139 6 14 92 6 23*
Aortic diastolic pressure
(mm Hg)
105 6 5 65 6 21†
MAP (mm Hg) 116 6 8 74 6 21*
LVEDP (mm Hg) 2 6 1 7 6 6*
Control Group
(n 5 6)
In Vitro
Diabetic Group
(n 5 9)
In Vitro
CPP (mm Hg) 133 6 52 135 6 31
Peak LV pressure (mm
Hg)
112 6 36 73 6 19‡
LVEDP (mm Hg) 4 6 5 5 6 4
Peak developed pressure
(mm Hg)
109 6 36 68 6 19‡
90% Relaxation time
(ms)
139 6 11 142 6 18
Peak 1dP/dt (mm Hg/s) 2,517 6 672 1,461 6 428‡
Peak 2dP/dt (mm Hg/s) 1,374 6 391 843 6 223‡
*p , 0.0001; †p , 0.001; ‡p , 0.05 control versus diabetic group. Data are presented
as the mean value 6 SEM.
CPP 5 coronary perfusion pressure; dP/dt 5 rate of change in left ventricular
pressure; LV 5 left ventricular; LVEDP 5 left ventricular end-diastolic pressure;
MAP 5 mean arterial pressure.
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data, and it provides important new insights into the
pathophysiology of diabetic cardiomyopathy as it relates to
the NO pathway. The Doppler echocardiographic findings
in the STZ-induced diabetic animals showed evidence of a
cardiomyopathy characterized by eccentric hypertrophy,
abnormal LV filling and systolic dysfunction. In vivo and in
vitro hemodynamic data revealed impaired systolic and
diastolic function. Diabetic animals were characterized by
lower exhaled NO levels, which were correlated with ab-
normal LV filling. We therefore postulate that a defect in
the NO pathway contributes to the cardiac dysfunction in
experimental diabetes mellitus, probably as a result of the
decreased availability of endothelial NO, as cardiac ecNOS
protein levels were similar between the two groups. In
addition, exhaled NO may serve as a noninvasive marker for
this myocardial dysfunction.
Doppler echocardiographic findings. The echocardio-
graphic finding of eccentric hypertrophy provides new
morphologic data not obtained previously from conven-
tional invasive hemodynamic data in animal models (8). By
integrating this morphologic data with the physiologic data
obtained in our study, it is apparent that a thickened and
stiff myocardium results in diastolic dysfunction character-
ized by elevated LV filling pressures. Extending this concept
of diastolic dysfunction to clinical practice provides a firm
basis for the hypothesis that diastolic dysfunction is one
mechanism by which diabetic patients have a higher inci-
dence of congestive heart failure in the absence of coronary
artery disease and in the post–myocardial infarction period,
the latter despite similar infarct sizes and ejection fractions,
as compared with nondiabetic patients (28).
Diastolic dysfunction. In our study, diastolic dysfunction
was characterized by impaired LV relaxation and increased
chamber stiffness. The finding of increased chamber stiff-
ness has not been a consistent finding in animal models (12)
and may relate to methodologic issues in calculating stiffness
or compliance (26). Some hemodynamic studies reporting
pressure–volume relations have noted upward or downward
shifts in response to a specific intervention (26). However,
because neither the slope nor the shape of the pressure–
volume relation was altered, this may not be due to a change
in chamber stiffness or compliance, and the term “distensi-
Figure 2. Diastolic pressure–volume relation. The LV diastolic pressure was measured 1 to 2 min after each increment of balloon volume.
To achieve comparable loading conditions (balloon volumes) in hearts of different sizes, the LV diastolic pressure was plotted versus
vol/volmax. The diabetic pressure–volume relation was shifted to the left, with a significant change in the shape of the curve, indicating
increased chamber stiffness. Line with triangles 5 diabetic animals; line with squares 5 control animals.
Figure 3. Relative ecNos expression. A representative immunoblot
of ecNOS in the LVs of control (Con) and diabetic (Diab) rats.
The last lane contains a human endothelial cell lysate (Human
endo) as a positive control. Note the apparent slight differences in
molecular weight between the rat and human ecNOS isoforms.
Quantification of band densities indicated no differences in the
relative levels of ecNOS between control and diabetic rats’ LVs.
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bility” has been suggested (26). We specifically evaluated the
shape of the pressure–volume curve in determining the
change in stiffness. To achieve comparable loading condi-
tions (i.e., balloon volumes) in hearts of different sizes, the
LV variables of interest were plotted versus vol/volmax. This
method of normalization has not been used in previous
studies and may also explain the discrepancies noted in these
studies as compared with ours. Although we did not
measure myocardial and interstitial collagen, they do not
appear to be consistently increased (8), suggesting that
metabolic or myocardial factors may play a significant role in
the increased chamber stiffness noted. This concept is
strengthened by the observation that insulin therapy cor-
rected the hemodynamic and mechanical abnormalities in a
rat model of diabetes mellitus, unassociated with histologic
changes (8). The LV end-diastolic pressure was elevated
with in vivo but not in vitro assessment. This may relate to
the influence of the constraining effect of the pericardium in
the closed-chest animal as opposed to the in vitro isolated
perfused heart (29).
Systolic dysfunction. Diabetic animals were characterized
by impaired systolic performance. This included a lower
peak-developed pressure and 1dP/dt in vitro, whereas
endocardial and midwall shortening did not differ between
diabetic and control animals, despite a lower wall stress in
the diabetic animals. These findings suggest that intrinsic
myocardial contractility was reduced in the diabetic animals.
The bradycardia noted in the diabetic group has been a
consistent finding (8,30). We excluded an influence of
bradycardia on the echocardiographic variables of LV dia-
stolic function by showing no correlation between heart rate
and diastolic relaxation and filling. In addition, slower heart
rates result in a smaller atrial contribution to ventricular
filling (31), yet despite bradycardia, we found a greater atrial
contribution to ventricular filling in the diabetic animals.
NO and diabetes. Nitric oxide is synthesized from
L-arginine by three different isoforms of the enzyme NO
synthase (ecNOS, a neuronal type [nNOS] and an inducible
enzyme iNOS), and this pathway is inhibited by L-arginine
analogues (32). The cardiac effects of NO are complex and
species-dependent, and the results have been conflicting in
terms of a beneficial or deleterious effect of NO. The direct
NO donor, nitroprusside, increased myocardial relaxation in
the isolated ejecting heart (33). Data from peripheral
vascular endothelial function in diabetic patients suggest
that endothelium-dependent vasodilation is impaired in
patients with diabetes mellitus and experimentally induced
hyperglycemia, and function can be restored by NO donors,
suggesting decreased availability of endothelial NO as a
contributor to endothelial dysfunction (5,6). However, in
direct contradistinction to these results, NO donors reduce
peak contractile performance and shorten the myocardial
contraction phase in humans (34). L-NAME, a nonselec-
tive inhibitor of NOS, improves ventricular performance in
isolated perfused diabetic hearts, suggesting a role for
increased NO in diabetic cardiomyopathy (35). Chronic
administration of the inducible NO synthase (iNOS) inhib-
itor, aminoguanidine, in diabetic rats improved the de-
creased myocardial compliance (19).
Exhaled NO. The development of chemiluminescence an-
alyzers has allowed the accurate measurement of NO in
exhaled air. The major sources of NO in expired air are the
nose and sinuses, with a lesser contribution from NO
produced in the lungs and airways (36). Pulmonary produc-
tion of NO probably arises from both pulmonary vascular
endothelium and pulmonary epithelial cells, as both consti-
tutive and inducible forms of NO synthase have been
identified in cells representative of bronchial epithelium and
type II alveolar pneumocytes (37). Nitric oxide produced by
the pulmonary vascular endothelium appears to function as
a pulmonary vasodilator (38). Nasal breathing leads to
higher concentrations of exhaled NO owing to contamina-
tion from NO produced in the paranasal sinuses and
nasopharynx (39). We eliminated upper airway contamina-
tion by sampling NO from tracheal intubation. It is unlikely
that NO produced by the peripheral circulation is elimi-
nated through the lungs, as NO is avidly bound to hemo-
globin, which results in its inactivation on reaching the
intravascular space (40). More specifically, we showed that
the decreased expired NO is not due to a lesser amount of
the enzyme ecNOS, but is more likely limited by substrate
availability. Although we did not measure ecNOS in the
lung, the reduced exhaled NO in the diabetic animals
probably is a marker for the generalized reduced availability
of NO. However, we cannot exclude lower lung levels of
ecNOS in the diabetic animals.
Study limitations. Although IVRT and filling patterns can
assess LV diastolic chamber function, under some circum-
stances they lack specificity (26). If the systolic pressure is
high, the IVRT can be prolonged, even if the relaxation
process is unchanged. The E/A ratio can be reduced despite
no change in relaxation and a decline in chamber stiffness
purely by lowering chamber preload. This would result in a
lower E wave velocity (reduced early filling pressure gradi-
ents between the left atrium and ventricle), but have
relatively less effect on the A wave. These factors do not
appear to play a major role in our study, as the systolic
pressure was lower in the diabetic animals and LV filling
showed a greater A wave with little effect on the E wave.
Although protein levels of ecNOS were similar in both
groups, we did not measure ecNOS function or messenger
ribonucleic acid expression. The localization of ecNOS was
not determined, but studies have reported ecNOS in coro-
nary endocardial endothelium (41,42) and cardiac myocytes
(43). Accelerated inactivation of NO is another potential
mechanism for decreased NO availability in diabetic rats
(44).
Clinical implications. Cardiovascular disease is a major
cause of morbidity and mortality in diabetic patients. In the
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absence of coronary artery disease, diabetic patients may
exhibit evidence of a cardiomyopathy (2). However, the
specific abnormality and how this cardiomyopathy relates to
the higher postinfarction mortality observed in diabetic
patients has not been well defined. We have shown in the
STZ-induced diabetic rat that the cardiomyopathy is char-
acterized by eccentric hypertrophy and both diastolic and
systolic dysfunction. Further, this observed diastolic dys-
function is correlated with reduced NO availability. This
constellation of pathologic findings elucidated by our study
represents several mechanisms by which diabetic patients
have a higher incidence of congestive heart failure in the
absence of coronary artery disease, and also in the post–
myocardial infarction period. Our data suggest that exhaled
NO may serve as a useful noninvasive marker for diabetic
myocardial dysfunction, and if validated in the clinical
setting, may be used both as an early marker for myocardial
dysfunction and to assess the effects of various therapeutic
strategies.
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